Time-kill assay and etest evaluation for synergy with polymyxin B and fluconazole against Candida glabrata

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5795-5800

  Pankey, George ^a   Ashcraft, Deborah ^a   Kahn, Heather ^a   Ismail, Abdulrahim ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POLYMYXIN B; ANTIFUNGAL AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA GLABRATA; CONTROLLED STUDY; DRUG POTENTIATION; EPSILOMETER TEST; FUNGUS ISOLATION; GENE SEQUENCE; GENOTYPE; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; TIME KILL ASSAY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG SYNERGISM; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B;

EID: 84907270598     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03035-14     Document Type: Article

References (24)

1. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(Suppl 1):S3-S13. http://dx.doi.org/10.1016/j.amjmed.2011.11.001.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance /threat-report-2013/index.html.
3. Lott TJ, Frade JP, Lockhart SR. 2010. Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eukaryot. Cell 9:619-625. http://dx.doi.org/10.1128/EC.00002-10.
4. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. 2012. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55:1352-1361. http://dx.doi.org/10.1093/cid/cis697.
5. Nicholls MWN. 1970. Polymyxin sensitivity of Candida tropicalis. J. Med. Microbiol. 3:529-537. http://dx.doi.org/10.1099/00222615-3-3-529.
6. Schwartz SN, Medoff G, Kobayashi GS, Kwan CN, Schlessinger D. 1972. Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. Antimicrob. Agents Chemother. 2:36-40. http://dx.doi.org/10.1128/AAC.2.1.36.
7. Zhai B, Zhou H, Yang L, Zhang J, Jung K, Giam CZ, Xiang X, Lin X. 2010. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 65:931-938. http://dx.doi.org/10 .1093/jac/dkq046.
8. Moneib NA. 1995. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J. Chemother. 7:525-529. http://dx.doi.org/10.1179/joc.1995.7.6 .525.
9. Pankey G, Ashcraft D. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, abstr M-1717.
10. Pankey G, Ashcraft D, Kahn H, Ismail A. 2014. Abstr. 12th ASM Conf. Candida Candidiasis, New Orleans, LA, abstr 133A.
11. CLSI. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
12. CLSI. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
13. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Pankey GA, Ashcraft DS, Dornelles A. 2013. Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species. Diagn. Microbiol. Infect. Dis. 77:220-226. http://dx.doi.org/10.1016/j.diagmicrobio.2013 .07.006.
15. Pillai SK, Moellering RC, Jr, Eliopoulos GM. 2005. Antimicrobial combinations, p 365-405. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
16. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
17. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
18. Borghi E, Iatta R, Sciota R, Biassoni C, Cuna T, Montagna MT, Morace G. 2010. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study. J. Clin. Microbiol. 48:3153-3157. http://dx.doi.org/10.1128/JCM.00952-10.
19. Arthington-Skaggs BA, Warnock DW, Morrison CJ. 2000. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 44:2081-2085. http://dx.doi.org/10.1128/AAC .44.8.2081-2085.2000.
20. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
21. bioMérieux Inc. 2013. Etest® antifungal susceptibility testing: package insert instructions. bioMérieux, Inc., Durham, NC.
22. Pankey GA, Ashcraft DS. 2005. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:2959-2964. http://dx.doi.org/10.1128 /AAC.49.7.2959-2964.2005.
23. Eliopoulos GM, Eliopoulos CT. 1988. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1:139-156.
24. Zhang Y-Q, Gamarra S, Garcia-Effron G, Park S, Perlin DS, Rao R. 2010. Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathog. 6:e1000939. http://dx.doi.org /10.1371/journal.ppat.1000939.